Determining the resistance to somatostatin analogues in pheochromocytomas and paragangliomas

#3853

Introduction: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine neoplasms (NENs) derived from chromaffin cells of the neural crest. Somatostatin analogues (SSAs) represent one of the pillars for NENs diagnosis/treatment due to the high density of somatostatin receptor (SSTs) in their membrane. However, although PPGLs share this characteristic, their response to SSAs is limited, being the reason underlying this unresponsiveness still unknown.

Aim(s): The main objective was to unravel the molecular underpinnings behind the lack of response to SSAs in PPGLs, with the ultimate aim to seek useful tools to overcome this obstacle.

Materials and methods: We analysed RNA-seq data of two distinct cohorts of 204 and 95 samples (Madrid, Marseille, Cordoba), and the TCGA dataset. For in vitro assays, we tested the response of rat PC-12 cells, and human SK-N-AS cells (wildtype and SDHB-KD) to somatostatin, cortistatin, octreotide and pasireotide.

Conference:

Presenting Author:

Authors: García Vioque V, Blázquez-Encinas R, Moreno Montilla M, Mangili F, Martínez Montes �,

Keywords: pheochromocytoma, paraganglioma, neuroendocrine tumor, somatostatin analogues, treatment resistance,